// App-Quantinova.ai

P6-07-21 : High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

Researchers

Presenter

  • L Manso Sánchez

Principal Investigators

  • F Moreno Antón

  • Y Izarzugaza Perón

  • I Delgado Mingorance

  • P Borrega García

  • MJ Echarri González

  • N Martínez Jáñez

  • A López González

  • C Olier Garate

  • A Ballesteros García

  • I Chacón López-Muñiz

  • EM Ciruelos Gil

  • JA García Sáenz

  • L Paz-Ares Rodríguez

Medical Centers

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Hospital Universitario Severo Ochoa, Las Matas, Spain

  • Hospital Ramon y Cajal, Madrid, Spain

  • Hospital of Leon, Leon, Spain

  • Hospital Universitario Infanta Cristina, Badajoz, Spain

  • Hospital Universitario Fundacion de Alcorcon, Alcorcon, Spain

  • Hosp San Pedro de Alcantara de Caceres, Caceres, Spain

  • Hospital La Paz, Madrid, Spain

  • Hospital Virgen de la Salud, Toledo, Spain

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Estrogens

  • Eribulin

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved